摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(cyclopropylmethoxy)benzaldehyde | 54280-77-2

中文名称
——
中文别名
——
英文名称
2-(cyclopropylmethoxy)benzaldehyde
英文别名
——
2-(cyclopropylmethoxy)benzaldehyde化学式
CAS
54280-77-2
化学式
C11H12O2
mdl
MFCD11156430
分子量
176.215
InChiKey
YPXZBUQPDJHULR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    13
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.363
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    2-(cyclopropylmethoxy)benzaldehyde 在 aluminium(III) triflate 、 tert-butylthiohypoiodite偶氮二甲酸二异丙酯三苯基膦 、 potassium hydroxide 作用下, 以 四氢呋喃 为溶剂, 反应 12.0h, 生成 tert-butyl 2-(6-cyano-1-(2-(2-(cyclopropylmethoxy)phenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-5-methyl-2,4-dioxo-1,2-dihydrothiopheno[2,3-d]pyrimidin-3(4H)-yl)-2-methylpropionate
    参考文献:
    名称:
    CYANO SUBSTITUTED HETEROARYLPYRIMIDINONE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
    摘要:
    本发明涉及一种由式(I)表示的氰基取代的杂环吡啶酮衍生物,其制备方法以及作为治疗剂的用途,特别是作为乙酰辅酶A羧化酶(ACC)抑制剂的用途,式(I)中每个取代基的定义与说明中的定义相同。
    公开号:
    US20200102322A1
  • 作为产物:
    描述:
    在 iron(III) chloride 、 tetramethyldisiloxane 作用下, 以 乙醇 为溶剂, 反应 12.0h, 以78%的产率得到2-(cyclopropylmethoxy)benzaldehyde
    参考文献:
    名称:
    在室温和环境空气中,铁催化的烯丙基芳烃的氧化性C–C(乙烯基)σ键裂解为芳基醛†
    摘要:
    据报道,在没有杂原子的帮助下,烯丙基芳烃的一般和选择性铁催化烯丙基的C–C(乙烯基)σ键裂解可得到芳基醛。无应变的碳-碳单键裂解反应使用环境空气作为唯一氧化剂,在室温下有效进行,并具有出色的官能团耐受性,从而解决了当前C-C键裂解/官能化的长期挑战。值得注意的是,该方法能够使复杂的生物活性分子快速后期氧化,并可用于加速从容易获得的化学原料中合成天然产物(香兰素和葡糖香兰素)。
    DOI:
    10.1039/c9cc01995b
点击查看最新优质反应信息

文献信息

  • [EN] HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS<br/>[FR] ANALOGUES D'HÉTÉROCYCLYL PYRAZOLOPYRIMIDINE EN TANT QU'INHIBITEURS DE JAK
    申请人:CELLZOME LTD
    公开号:WO2011048082A1
    公开(公告)日:2011-04-28
    The present invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    本发明涉及式(I)的化合物,其中X1至X5,Y,Z1至Z3和R的含义如描述和权利要求中所述。所述化合物可用作JAK抑制剂,用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫介导性疾病。该发明还涉及包括所述化合物的药物组合物,以及制备这类化合物以及用作药物的用途。
  • FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS
    申请人:Lingham Prasada Rao V.S.
    公开号:US20090286811A1
    公开(公告)日:2009-11-19
    The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
    本发明提供了瞬时受体电位香草酰基(TRPV)调节剂。具体而言,本文描述的化合物对于治疗或预防TRPV3调节的疾病、病况和/或障碍非常有用。本文还提供了制备上述化合物的过程、用于合成的中间体、它们的制药组合物以及治疗或预防TRPV3调节的疾病、病况和/或障碍的方法。
  • HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS
    申请人:Ramsden Nigel
    公开号:US20120252779A1
    公开(公告)日:2012-10-04
    The invention relates to compounds of formula (I) wherein X 1 to X 5 , Y, Z 1 to Z 3 , and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    本发明涉及公式(I)的化合物,其中X1至X5,Y,Z1至Z3和R的含义如所述及权利要求中所述。所述化合物可用作JAK抑制剂,用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫介导性疾病。本发明还涉及包括所述化合物的制药组合物、制备这种化合物以及用作药物的用途。
  • Fused pyrimidineone compounds as TRPV3 modulators
    申请人:Glenmark Pharmaceuticals S.A.
    公开号:US08119647B2
    公开(公告)日:2012-02-21
    The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
    本发明提供了瞬时受体电位香草酰基转移酶(TRPV)调节剂。特别地,本文所描述的化合物可用于治疗或预防受TRPV3调节的疾病、病况和/或疾病。本文还提供了制备所述化合物的过程,用于其合成的中间体,其制药组成物以及治疗或预防受TRPV3调节的疾病、病况和/或疾病的方法。
  • EP1 RECEPTOR LIGANDS
    申请人:Torrens Jover Antoni
    公开号:US20140323475A1
    公开(公告)日:2014-10-30
    The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.
    本发明属于EP1受体配体领域,更具体地,它指的是具有EP1受体亲和力和选择性的一般式(I)化合物。该发明还涉及它们的制备过程,它们作为治疗和/或预防由EP1受体介导的疾病或疾病的药物的使用,以及包含它们的制药组合物。
查看更多